Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 2, pp 491–491 | Cite as

Early recognition of coeliac disease through community pharmacies: a proof of concept study

  • Heidi Urwin
  • David WrightEmail author
  • Michael Twigg
  • Norma McGough
Letter to the Editor

Keywords

Public Health Peptide Internal Medicine False Negative Result Early Recognition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Dear Editor,

In the publication of our proof of concept study [1], we incorrectly described the point of care test Simtomax® as measuring both total IgA and IgA tTG antibodies. The test detects total IgA, recommended by NICE, and both IgA and IgG antibodies against deamidated gliadin peptides, ensuring those with IgA deficiency are identified, reducing the risk of false negative results. The revised NICE guideline for coeliac disease acknowledges the rising evidence of point of care tests and as a result removed the statement ‘do not use point of care tests’ from their previous guidance [2].

References

  1. 1.
    Urwin H, Wright D, Twigg M, McGough N. Early recognition of coeliac disease through community pharmacies: a proof of concept study. Int J Clin Pharm. 2016;38:1294–300.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    National Institute for Health and Care Excellence. NICE guideline NG20; Coeliac disease; recognition, assessment and management 2015 [cited 2016 Aug 3] Available from: https://www.nice.org.uk/guidance/ng20.

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  1. 1.School of PharmacyUniversity of East AngliaNorwichUK
  2. 2.Coeliac UKHigh WycombeUK

Personalised recommendations